EVEREST STUDY: Efficacy and Safety of Verteporfin Photodynamic Therapy in Combination with Ranibizumab or Alone Versus Ranibizumab Monotherapy in Patients with Symptomatic Macular Polypoidal Choroidal Vasculopathy
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Methods: In this multicenter, double-masked, primarily indocyanine green angiography–guided trial, 61 Asian patients were randomized to verteporfin PDT (standard fluence), ranibizumab 0.5 mg, or the combination. Patients were administered with verteporfin PDT/placebo and initiated with three consecutive monthly ranibizumab/sham injections starting Day 1, and re-treated (Months 3–5) as per predefined criteria. The primary endpoint was the proportion of patients with indocyanine green angiography–assessed complete regression of polyps at Month 6. Secondary endpoints included mean change in best-corrected visual acuity at Month 6 and safety. Results: At Month 6, verteporfin combined with ranibizumab or alone was superior to ranibizumab monotherapy in achieving complete polyp regression (77.8% and 71.4% vs. 28.6%; P < 0.01); mean change ± standard deviation in best-corrected visual acuity (letters) was 10.9 ± 10.9 (verteporfin PDT + ranibizumab), 7.5 ± 10.6 (verteporfin PDT), and 9.2 ± 12.4 (ranibizumab). There were no new safety findings with either drug used alone or in combination. Conclusion: Verteporfin PDT combined with ranibizumab 0.5 mg or alone was superior to ranibizumab monotherapy in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular polypoidal choroidal vasculopathy. All treatments were well tolerated over 6 months. EVEREST, the first, multicenter, double-masked, primarily indocyanine green angiography–guided randomized controlled trial for symptomatic macular polypoidal choroidal vasculopathy, demonstrated superiority of verteporfin photodynamic therapy combined with ranibizumab or alone over ranibizumab monotherapy in achieving complete regression of polyps at Month 6. Best-corrected visual acuity improved in all treatment arms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the United Kingdom, ICGA is not available in all units and is usually reserved for cases presenting with clinical features suspicious of polypoidal choroidopathy (IPCV) or retinal angiomatous proliferation (RAP) or when response to anti-VEGF therapy is suboptimal.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“Some lesion types are thought to be less responsive than others to anti-VEGF therapy, for example, IPCV.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“The EVEREST study suggested that combination therapy of IPCV with photodynamic therapy (PDT) and ranibizumab led to a better outcome than monotherapy with ranibizumab.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“However, an expanding or increased elevation in PED indicates activity that merits evaluation and treatment.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
Citations
Cites
Chung, S. E., Kang, S. W., Lee, J. H., & Kim, Y. T. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.012 · Cited by 580
Polypoidal Choroidal Vasculopathy: Incidence, Demographic Features, and Clinical Characteristics
Sho, K. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.10.1392 · Cited by 439 · cited 1×
“Moreover, the incidence of sub-RPE hemorrhage or subretinal hemorrhage in patients with PCV is high (30%–64%).(3,9) In a study of the natural history of patients with PCV, Uyama et al(6) reported that half of the study eyes had hemorrhagic episodes, recurrent leakage, or severe RPE atrophy after a long follow-up perio…”
BackgroundThe Expanding Clinical Spectrum of Idiopathic Polypoidal Choroidal Vasculopathy
Yannuzzi, L. A. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100150480005 · Cited by 436 · cited 3×
“It may be associated with a branching vascular network (BVN) and clinically visible orange-red subretinal nodule(s).(1) Polypoidal choroidal vasculopathy is prevalent in 10% to 54% of the Asian patients and in 8% to 12% of white patients with presumed exudative age-related macular degeneration (AMD).”
BackgroundPolypoidal choroidal vasculopathy: natural history
Uyama, M., Wada, M., Nagai, Y., Matsubara, T., Matsunaga, H., Fukushima, I., Takahashi, K., & Matsumura, M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01404-6 · Cited by 402 · cited 3×
“In PCV, the polypoidal lesions originate from the inner choroidal vasculature and can progress beneath the RPE.(1,6,7) The presence of orange-red nodule–like structures beneath the RPE associated with an adjacent serous pigment epithelial detachment or overlying neurosensory detachment, subretinal hemorrhage, and lipi…”
BackgroundTong, J.-P., Chan, W.-M., Liu, D. T. L., Lai, T. Y. Y., Choy, K.-W., Pang, C.-P., & Lam, D. S. C. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.10.012 · Cited by 385 · cited 1×
“The increased expression of VEGF in the aqueous humor of eyes with PCV provides a biologic rationale for treatment with anti-VEGF agents.(19) Limited data from case series with bevacizumab monotherapy have shown that treatment may reduce leakage associated with PCV but is ineffective for complete regression of the pol…”
BackgroundSelf-citationPhotodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy
Chan, W.-M., Lam, D. S. C., Lai, T. Y. Y., Liu, D. T. L., Li, K. K. W., Yao, Y., & Wong, T.-H. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.12.056 · Cited by 283
Self-citation(2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00223-x · Cited by 274 · cited 1×
“For CNV secondary to AMD, the Verteporfin In Photodynamic Therapy and the Treatment of AMD with Photodynamic Therapy study has demonstrated that there was gradual visual deterioration or no visual improvement with high re-treatment rate at 6 months for treated patients after verteporfin PDT administration.(25) This tr…”
ResultEfficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy
Gomi, F., Sawa, M., Sakaguchi, H., Tsujikawa, M., Oshima, Y., Kamei, M., & Tano, Y. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.122283 · Cited by 242 · cited 1×
“These findings are consistent with those reported earlier with other anti-VEGF therapies.(20,21)”
ResultGomi, F., Ohji, M., Sayanagi, K., Sawa, M., Sakaguchi, H., Oshima, Y., Ikuno, Y., & Tano, Y. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.02.031 · Cited by 239
The origins of polypoidal choroidal vasculopathy
Yuzawa, M. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.049296 · Cited by 198 · cited 4×
“Use of dynamic confocal scanning laser ophthalmoscope–ICGA may assist in further elucidating the BVN, from which these focal evaginating nodules arise, enabling clearer definition and differentiation from exudative AMD because of CNV.(7) Based on ICGA findings, PCV is defined as the presence of single or multiple foca…”
BackgroundInfluential
Cited by
Items 201–300 of 586
Demirel, S., Yanık, Ö., Özcan, G., Batıoğlu, F., & Özmert, E. (2021) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-021-00829-5 · Cited by 18
“The differential diagnosis of PCV depended on the criteria defined by the EVEREST study [9].”
MethodLin, T., Hwang, D., Lee, F.-L., & Chen, S. (2016) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2015.11.004 · Cited by 18
Self-citationKim, K. H., Kim, J. H., Chang, Y. S., Lee, T. G., Kim, J. W., & Lew, Y. J. (2015) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2015.29.5.315 · Cited by 19
“Although anti-VEGF therapy has been found to be effective in previous studies [29,30], its efficacy is generally inferior to that of photodynamic therapy for polyp regression [31].”
BackgroundCurrent Management of Polypoidal Choroidal Vasculopathy
Tan, C. S., Lim, T. H., & Hariprasad, S. M. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20150909-02 · Cited by 18
Self-citationGeographic atrophy phenotype identification by cluster analysis
Monés, J., & Biarnés, M. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-310268 · Cited by 19
Kimura, S., Morizane, Y., Matoba, R., Hosokawa, M. M., Shiode, Y., Hirano, M., Doi, S., Toshima, S., Takahashi, K., Hosogi, M., et al. (2017) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-017-0530-0 · Cited by 20
Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan
Chen, L.-J., Cheng, C., Yeung, L., Yang, C., Chen, S., Chen, J., Chen, L.-J., Chen, S.-N., Chen, W., Cheng, C., et al. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.04.012 · Cited by 20
Self-citationArnold‐Vangsted, A., Schou, M. G., Balaratnasingam, C., Cehofski, L. J., Chhablani, J. K., van Dijk, E. H. C., Eriksen, N. S., Grauslund, J., Hajari, J. N., Sabaner, M. C., et al. (2024) · Acta Ophthalmologica · doi:10.1111/aos.16797 · Cited by 25
“%) at 6 months (Koh et al., 2012).”
Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy
Videkar, C., Kapoor, A., Chhablani, J. K., & Narayanan, R. (2015) · BMJ Case Reports · doi:10.1136/bcr-2015-212988 · Cited by 17
Wongchaisuwat, P., Thamphithak, R., Jitpukdee, P., & Wongchaisuwat, N. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.10.16 · Cited by 17
Shin, J. Y., Choi, M., Chung, B., & Byeon, S. H. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-2977-3 · Cited by 17
“Furthermore, studies of anti-VEGF monotherapy have reported that treatment reduced leakage associated with PCV, but the treatment was less effective for regression of the polypoidal dilations [13].”
BackgroundPolypoidal choroidal vasculopathy treatment options: A meta‐analysis
Qian, T., Li, X., Zhao, M., & Xu, X. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12840 · Cited by 17
“Many studies have reported that PDT may lead to an increased risk of intraretinal or subretinal haemorrhage, thereby resulting in ischaemic damage to normal choroidal tissue.(16,17,22-25) Among them, subretinal haemorrhage, the most common and most reported adverse event, may also limit visual improvement following PD…”
BackgroundDíaz-Villamarín, X., Blánquez-Martínez, D., Pozo-Agundo, A., Pérez-Gutiérrez, A. M., Muñoz‐Ávila, J. I., Antúnez-Rodríguez, A., Fernández-Gómez, A. E., García-Navas, P., Martínez-González, L. J., & Dávila-Fajardo, C. L. (2020) · Genes · doi:10.3390/genes11111335 · Cited by 19
Tan, C. S., Ngo, W. K., Lim, L. W., Tan, N., & Lim, T. H. (2019) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13464 · Cited by 17
“3,6–8 While nAMD has been shown to respond well to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, studies have demonstrated better rates of polyp regression and improvements in visual acuity among patients receiving combination therapy with photodynamic therapy (PDT) and intravitreal ranibizumab.(9,1…”
BackgroundMethodInfluentialSelf-citationAndroudi, S. N., Δαστιρίδου, Ά., Pharmakakis, N. M., Stefaniotou, M. I., Kalogeropoulos, C. D., Symeonidis, C., Charonis, A. C., & Tsilimbaris, M. K. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0332-7 · Cited by 20
Azuma, K., Obata, R., Nomura, Y., Tan, X., Takahashi, H., & Yanagi, Y. (2016) · Retina · doi:10.1097/iae.0000000000001047 · Cited by 17
TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: One-Year Results
Pak, K. Y., Park, S. W., Byon, I. S., & Lee, J. E. (2016) · Retina · doi:10.1097/iae.0000000000001195 · Cited by 16
“In particular, both conditions are mainly treated by intravitreal injection of anti-vascular endothelial growth factor (VEGF).(6,7) However, patients require life-long disease manage-”
BackgroundBaek, J., Lee, J. H., & Lee, W. K. (2016) · Retina · doi:10.1097/iae.0000000000001284 · Cited by 16
Self-citationSaito, M., Kano, M., Itagaki, K., & Sekiryu, T. (2016) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-016-0478-5 · Cited by 17
“6 %) eyes in the ranibizumab monotherapy group [11].”
BackgroundInfluentialANGIOGRAPHIC SUBTYPES OF POLYPOIDAL CHOROIDAL VASCULOPATHY IN TAIWAN
Yeung, L., Kuo, C.-N., Chao, A., Chen, K., Wu, W., Lai, C., Wang, N., Hwang, Y., Chen, C., & Lai, C. (2017) · Retina · doi:10.1097/iae.0000000000001556 · Cited by 16
Liu, L., Tham, Y. C., Wu, J., Yue, S., & Cheng, C. (2017) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2017.09.008 · Cited by 16
“multicenter, randomized, active controlled, double-masked, exploratory study [10] showed that the mean change in BCVA from baseline to 6month was 9.”
BackgroundMethodMiotto, S., Zemella, N., Gusson, E., Panozzo, G., Saviano, S., Scarpa, G., Boschi, G., Piermarocchi, S., & on behalf of the Italian GAT (Gruppo Angiografico Triveneto) Study Group (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0022 · Cited by 18
Li, X., Zhu, Q., Egger, A., Liu, C., Wolf, S., Song, Y., Zhang, J., Dong, F., Xu, X., & Weisberger, A. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14588 · Cited by 17
“Ranibizumab and verteporfin photodynamic therapy (PDT; Visudyne ; Novartis AG, Switzerland; verteporfin PDT) have been effective in the regression of polyps and improvement of vision in Asian patients with PCV (Koh et al. 2012; Oishi et al. 2013; Gomi et al. 2015; Koh et al. 2017; Chen et al. 2018).”
BackgroundMethodResultInfluentialSelf-citationTrends in Age‐Related Macular Degeneration Management in Singapore
Ng, W. Y., Cheung, C. M. G., Mathur, R., Chan, C. M., Yeo, I. Y. S., Wong, E. Y., Lee, S. Y., Loh, B. K., Wong, D., & Wong, T. Y. (2014) · Optometry and Vision Science · doi:10.1097/opx.0000000000000283 · Cited by 19
“The role of anti-VEGF monotherapy in PCV is uncertain,(24) and combination therapy with PDT is often practiced.(28,29) It has been hypothesized that the addition of PDT to anti-VEGF therapy may reduce the total number of injections.”
BackgroundChanging paradigms of anti-VEGF in the Indian scenario
Shanmugam, P. (2014) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.126189 · Cited by 16
“Mont Blanc and Everest studies found that the effi cacy of the combination was similar to that of anti-VEGF montherapy.[70,71] Kumar et al.”
ResultBae, K., Noh, S. R., Kang, S. W., Kim, E. S., & Yu, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-46235-3 · Cited by 16
A History of Anti-VEGF Inhibitors in the Ophthalmic Literature: A Bibliographic Review
Whitescarver, T. D., Hobbs, S. D., Wade, C. I., Winegar, J. W., Colyer, M. H., Reddy, A. K., Drayna, P., & Justin, G. A. (2020) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126420971982 · Cited by 16
Pachychoroid neovasculopathy: A comparative review on pathology, clinical features, and therapy
Sagar, P., Sodhi, P. S., Roy, S., Takkar, B., & Azad, S. V. (2021) · European Journal of Ophthalmology · doi:10.1177/11206721211036290 · Cited by 15
da Silva, R. M., Arias, L., Nunes, S. G., Farinha, C., Coimbra, R., Marques, J. P., Cachulo, M. L., Figueira, J., Barreto, P., Madeira, M. H., et al. (2021) · Ophthalmologica · doi:10.1159/000518235 · Cited by 17
Self-citationSaito, M., Iida, T., Kano, M., & Itagaki, K. (2013) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-013-2433-1 · Cited by 15
Miura, M., Nemoto, Iwasaki, & Goto (2012) · Clinical ophthalmology · doi:10.2147/opth.s37252 · Cited by 15
Pron, G. (2014) · PubMed Central · Cited by 19
Polypoidal Choroidal Vasculopathy
Kim, J.-B., Nirwan, R. S., & Kuriyan, A. E. (2017) · Current Ophthalmology Reports · doi:10.1007/s40135-017-0137-0 · Cited by 15
Nagai, N., Ibuki, M., Shinoda, H., Kameyama, K., Tsubota, K., & Ozawa, Y. (2017) · Medicine · doi:10.1097/md.0000000000006965 · Cited by 16
“The EVEREST study, a clinical study on PDT, reported higher rates of polyp regression among patients treated by PDT than among patients who received ranibizumab monotherapy,([14])”
BackgroundSUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY
Wong, D. T., Lambrou, G. N., Loewenstein, A., Pearce, I., & Okada, A. A. (2020) · Retina · doi:10.1097/iae.0000000000002713 · Cited by 15
Wang, J., & Yin, L.-R. (2020) · Journal of Ophthalmology · doi:10.1155/2020/9503795 · Cited by 15
Cheng, Y., Shi, X., Qu, J., Zhao, M., & Li, X. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.192779 · Cited by 15
“By 12 months, Koh et al.[22] reported a polyp regression rate of 24.2% in the bevacizumab group and 23.3% in the ranibizumab group after receiving 3 monthly injections followed by as‑needed Figure 3: Mean BCVA (a), CRT (b), SRF (c), and PED (d) changes between two PCV subgroups over 12 months, *P < 0.05.”
BackgroundInfluentialBhoomibunchoo, C., Yospaiboon, Y., Thoongsuwan, S., Rojanaporn, D., Watanachai, N., Jirarattanasopa, P., Wongcumchang, N., Amphornphruet, A., Vongkulsiri, S., & Arayangkoon, E. (2017) · Clinical ophthalmology · doi:10.2147/opth.s126226 · Cited by 15
“Based on the EVEREST study,(19) the patients were diagnosed as having IPCV by the presence of early subretinal focal ICGA hyperfluorescence (appearing within the first 6 minutes after the injection of indocyanine green) and, in addition, at least one of the following angiographic or clinical criteria: 1) polyp-like le…”
Alasil, T., Munoz, N., Keane, P. A., Tufail, A., Coady, P. A., Novais, E. A., de Carlo, T. E., Baumal, C. R., Waheed, N. K., Duker, J. S., et al. (2017) · International Journal of Retina and Vitreous · doi:10.1186/s40942-017-0060-4 · Cited by 16
Wong, D. T., Berger, A. R., Bourgault, S., Chen, J. L., Colleaux, K. M., Cruess, A. F., Dookeran, R. I., Gauthier, D., Hurley, B. R., Kapusta, M. A., et al. (2021) · Ophthalmologica · doi:10.1159/000516108 · Cited by 17
Polypoidal Choroidal Vasculopathy
Teo, K. Y. C., Zhao, J. Z., Klose, G., Lee, W. K., & Cheung, C. M. G. (2023) · Ophthalmology Retina · doi:10.1016/j.oret.2023.11.001 · Cited by 14
Self-citationSakai, T., Ohkuma, Y., Kohno, H., Hayashi, T., Watanabe, A., & Tsuneoka, H. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305189 · Cited by 14
Cho, H. J., Han, S. Y., Kim, H. S., Lee, T. G., & Kim, J. W. (2014) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-014-0349-x · Cited by 14
Self-citationHirakata, T., Fujinami, K., Watanabe, K., Sasaki, M., Noda, T., & Akiyama, K. (2016) · Clinical ophthalmology · doi:10.2147/opth.s101596 · Cited by 15
Zarbin, M. A., Francom, S. F., Grzeschik, S. M., Tuomi, L., Hašková, Z., Macfadden, W., Margaron, P., Snow, H., Cruess, A. F., Staurenghi, G., et al. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.04.018 · Cited by 16
Chaikitmongkol, V., Upaphong, P., Patikulsila, D., Jirarattanasopa, P., Choovuthayakorn, J., Watanachai, N., Kunavisarut, P., Ratanasukon, M., Bhurayanontachai, P., Ingviya, T., et al. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.03.012 · Cited by 14
Okada, A. A., Takahashi, K. A., Ohji, M., Moon, S. C., Machewitz, T., Sasaki, K., The ALTAIR Study Investigators, Ohji, M., Hanemoto, T., Kaga, T., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02162-w · Cited by 14
“Current treatment modalities for PCV include anti-VEGF monotherapy, photodynamic therapy (PDT) with verteporfin, and combination therapy with PDT and anti-VEGF therapy [2, 13].”
MethodMatsumiya, W., Honda, S., Otsuka, K., Miki, A., Nagai, T., Imai, H., Kusuhara, S., & Nakamura, M. (2015) · Ophthalmologica · doi:10.1159/000431000 · Cited by 14
Kokame, G. T., Shantha, J. G., Hirai, K., & Ayabe, J. (2016) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20160808-07 · Cited by 14
Genome-wide association study of neovascular age-related macular degeneration in the Thai population
Ruamviboonsuk, P., Tadarati, M., Singhanetr, P., Wattanapokayakit, S., Kunhapan, P., Wanitchanon, T., Wichukchinda, N., Mushiroda, T., Akiyama, M., Momozawa, Y., et al. (2017) · Journal of Human Genetics · doi:10.1038/jhg.2017.72 · Cited by 15
Self-citationKang, H. G., Kang, H., Byeon, S. H., Kim, S. S., Koh, H. J., Lee, S. C., & Kim, M. (2018) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13198 · Cited by 17
“sumed exudative age-related macular degeneration (AMD).(3) Studies regarding the natural history”
BackgroundChen, S., Cheng, C., Yeung, L., Chen, J., Chan, W., Liu, J., Sheu, S., Wu, W., & Lai, C. (2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.11.11 · Cited by 14
Self-citationPachydrusen in polypoidal choroidal vasculopathy in an Indian cohort
Chhablani, J. K., Singh, S., Chakurkar, R., Goud, A., Rasheed, M. A., & Vupparaboina, K. K. (2019) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1757_18 · Cited by 15
Matsumoto, H., Hoshino, J., Numaga, S., Asatori, Y., & Akiyama, H. (2025) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-025-01229-9 · Cited by 13
“Prior research has demonstrated that the rates of complete polypoidal lesion regression following 3 monthly anti-VEGF injections were 23-33% with ranibizumab [14–16], 42-57% with aflibercept 2 mg [13, 17–19], 79-82% with brolucizumab [8, 9, 19, 20], and 50-61% with faricimab [10, 11].”
Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
Soman, M., Nair, I. J., Sheth, J. U., & Nair, U. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00507-w · Cited by 13
“Ranibizumab is a humanized monoclonal antibody that binds with VEGF-A isoforms and prevents its interaction with its receptors on endothelial cells surface [7].”
BackgroundResultInfluentialPark, U. C., Shin, J. Y., Chung, H., & Yu, H. G. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0631-z · Cited by 14
“[13, 14] Furthermore, PDT-related complications such as subretinal hemorrhage and retinal pigment epithelium (RPE) tear are another reason to prefer anti-VEGF for the treatment of PCV.”
BackgroundWolff, B., Vasseur, V., Cahuzac, A., Coscas, F., Castelnovo, L., Favard, C., Michel, G., Français, C., Salomon, L., & Mauget‐Faÿsse, M. (2018) · Ophthalmologica · doi:10.1159/000488808 · Cited by 14
Fukuda, Y., Sakurada, Y., Sugiyama, A., Yoneyama, S., Matsubara, M., Kikushima, W., Tanabe, N., Parikh, R., & Kashiwagi, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082459 · Cited by 14
Maunz, A., Benmansour, F., Li, Y., Albrecht, T., Zhang, Y., Arcadu, F., Zheng, Y., Madhusudhan, S., & Sahni, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060524 · Cited by 14
Diagnosis of Polypoidal Choroidal Vasculopathy From Fluorescein Angiography Using Deep Learning
Tsai, Y.-Y., Lin, W.-Y., Chen, S., Ruamviboonsuk, P., King, C.-H., & Tsai, C.-L. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.2.6 · Cited by 13
Self-citationMathew, R., Pefkianaki, M., Kopsachilis, N., Brar, M., Richardson, M., & Sivaprasad, S. (2013) · Ophthalmologica · doi:10.1159/000355091 · Cited by 13
Peng, Y., Zhang, X., Li, M., Liu, B., Mi, L., Zuo, C., & Wen, F. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s158368 · Cited by 15
Lin, T., Dans, K., Müftüoğlu, İ. K., Meshi, A., Amador-Patarroyo, M. J., Cheng, L., & Freeman, W. R. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-313447 · Cited by 14
“32 In AMD, a vision of 20/200 is usually associated with a disciform scar or central geographic atrophy.”
BackgroundKoh, A., Lai, T. Y. Y., Wei, W. B., Mori, R., Wakiyama, H., Park, K. H., Ngah, F., Macfadden, W., Dunger‐Baldauf, C., & Parikh, S. (2019) · Retina · doi:10.1097/iae.0000000000002624 · Cited by 13
Self-citationROUVAS, A. A., Gouliopoulos, N., Douvali, M., Koutsocheras, G., Theodorou, M., Bouratzis, N., Bougatsou, P., & THEODOSSIADIS, P. G. (2021) · European Journal of Ophthalmology · doi:10.1177/11206721211014717 · Cited by 12
Kimura, T., Araki, T., Yasukawa, T., Kato, A., Kuwayama, S., Kinoshita, T., Okamoto, F., Murakami, T., Mitamura, Y., Sakamoto, T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274508 · Cited by 12
“Polyp regression is important for the prevention of SMH, and various clinical studies have shown that anti-vascular endothelial growth factor (VEGF) therapy is effective for PCV [6, 7].”
BackgroundArai, Y., Takahashi, H., Inoda, S., Tan, X., Sakamoto, S., Inoue, Y., Fujino, Y., Kawashima, H., & Yanagi, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229342 · Cited by 11
“To diagnose typical nAMD, PCV [15], and retinal angiomatous proliferation, both fluorescein and indocyanine green angiography were performed routinely for nAMD cases at our institution, with some exceptions (e.”
BackgroundInfluentialWada, I., Shiose, S., Ishikawa, K., Kano, K., Notomi, S., Mori, K., Akiyama, M., Nakao, S., & Sonoda, K. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05553-5 · Cited by 14
Lees, J. S., Dobbin, S. J. H., Elyan, B. M. P., Gilmour, D. F., Tomlinson, L. A., Lang, N. N., & Mark, P. B. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac305 · Cited by 14
Lee, J. H., & Lee, W. K. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3092-1 · Cited by 12
“Since the rates of complete polyp regression induced by anti-VEGF drugs were less than 30 % in previous studies [20, 28], grape-like polyps, the malignant form of polypoidal lesions in our patients, were not likely to regress completely with anti-VEGF treatment.”
BackgroundSelf-citationChung, Y.-R., Seo, E. J., Kim, Y. H., Yang, H. S., & Lee, K. (2016) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2016.02.012 · Cited by 14
Lai, K., Li, Y., Zhou, L., Zhong, X., Huang, C., Xu, F., Lü, L., Ge, J., & Jin, C. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0801-7 · Cited by 13
“The EVEREST study was the first randomized controlled trial evaluating the treatment outcomes of verteporfin PDT with or without ranibizumab versus ranibizumab monotherapy and their data showed that the PDT treatment had a superior efficacy in the closure of PCV polyps compared with the ranibizumab monotherapy althoug…”
BackgroundMethodOgura, Y., Iida, T., Lee, W. K., Cheung, C. M. G., Mitchell, P., Leal, S., Schmelter, T., & Ishibashi, T. (2021) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-020-00805-5 · Cited by 12
Self-citationLoo, J., Teo, K. Y. C., Vyas, C. H., Jordan-Yu, J. M., Juhari, A., Jaffe, G. J., Cheung, C. M. G., & Farsiu, S. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100292 · Cited by 12
Nakai, S., Matsumiya, W., Keiko, O., Miki, A., Nakamura, M., & Honda, S. (2018) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-018-0636-z · Cited by 10
Hyogo Macular Disease Study Group, Miki, A., Honda, S., Kojima, H., Nishizaki, M., Nagai, T., Fujihara, M., Uenishi, M., Kita, M., Kurimoto, Y., et al. (2013) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-013-0237-9 · Cited by 11
“Recently, results of a multicenter study conducted to compare the effects of PDT and ranibizumab therapy in patients with PCV showed that both therapies as well as their combination (PDT ? ranibizumab) therapy resulted in improvements in the patients’ visual acuity at 6 months posttreatment [29].”
ResultPOLYPOIDAL CHOROIDAL VASCULOPATHY SECONDARY TO A STABLE CHOROIDAL NEVUS
Wong, J., Lai, X. J., Sarafian, R. Y., Wong, H. S., & Smith, J. B. (2015) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000233 · Cited by 11
Wong, J., & Qian, K. Y. (2017) · Case Reports in Ophthalmology · doi:10.1159/000468144 · Cited by 12
Yang, J., Yuan, M., Wang, E., Xia, S., & Chen, Y. (2019) · BMC Ophthalmology · doi:10.1186/s12886-019-1245-4 · Cited by 11
Simão, J., Farinha, C., Marques, J. P., Nunes, S. G., Pires, I., Cachulo, M. L., Figueira, J., Murta, J., & da Silva, R. M. (2021) · Ophthalmologica · doi:10.1159/000515295 · Cited by 11
Anantharaman, G., Jain, P., Gopalakrishnan, M., & Goyal, A. (2018) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1222_17 · Cited by 11
Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept
Liu, H., Ma, Y., Xu, H.-C., Huang, L., Zhai, L., & Zhang, X. (2020) · Current Eye Research · doi:10.1080/02713683.2020.1781193 · Cited by 13
Tanaka, N., Azuma, K., Aoki, S., Kitamoto, K., Ueda, K., Fujino, R., Inoue, T., & Obata, R. (2024) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-024-06387-z · Cited by 11
“Moreover, anti-VEGF therapy combined with PDT has been proven to be effective for MNV with polypoidal lesions [9].”
Moraru, A. D., Danielescu, C., Iorga, R. E., Moraru, R., Zemba, M., & Brănişteanu, D. C. (2024) · Life · doi:10.3390/life14101220 · Cited by 12
“Nevertheless, several studies (EVEREST, LAPTOP, PLANET, EPIC) have shown that both functional and morphological results are better when PCV is treated with intravitreal anti-VEGF therapy, either as monotherapy or in combination with photodynamic therapy [64–67].”
BackgroundHuang, Y.-M., Hsieh, M., Li, A.-F., & Chen, S. (2017) · Journal of Ophthalmology · doi:10.1155/2017/3479695 · Cited by 10
Self-citationIntravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy
Cho, H. J., Kang, K. H., Yoon, W., Lee, J., Kim, C. G., & Kim, J. W. (2023) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2023.0030 · Cited by 12
Stereotactic Radiotherapy for Polypoidal Choroidal Vasculopathy: A Pilot Study
Introini, U., Casalino, G., Triolo, G., O’Shaughnessy, D., Shusterman, E. M., Chakravarthy, U., Slakter, J. S., & Bandello, F. M. (2014) · Ophthalmologica · doi:10.1159/000368561 · Cited by 10
Takayama, K., Kaneko, H., Kataoka, K., Ueno, S., Piao, C., Ito, Y., & Terasaki, H. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3468-x · Cited by 10
Arakawa, A., Inoue, M., Sato, S., Yamane, S., & Kadonosono, K. (2017) · Clinical ophthalmology · doi:10.2147/opth.s129164 · Cited by 11
Lin, T., Dans, K., Meshi, A., Müftüoğlu, İ. K., Amador-Patarroyo, M. J., Chen, K. C., Cheng, L., & Freeman, W. R. (2018) · Retina · doi:10.1097/iae.0000000000002272 · Cited by 10
Qi, H., Jin, E., & Zhao, M. (2019) · International Journal of Ophthalmology · doi:10.18240/ijo.2019.01.08 · Cited by 11
Ye, L., Cai, Y., Shi, X., Wong, I. Y., Qu, J., Zhao, M., Ying, X., & Li, X. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04988-y · Cited by 10
Rishi, P., Rishi, E., Sharma, M., Maitray, A., Bhende, M. P., Gopal, L., Sharma, T., Ratra, D., Sen, P., Bhende, P., et al. (2017) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_174_17 · Cited by 10
Ngo, W. K., Chee, W. K., Tan, C. S., & Lim, T. H. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01419-8 · Cited by 10
“The EVEREST and EVEREST II studies demonstrated that the value of standard PDT in the treatment of PCV lies in its superior efficacy to close the active polypoidal lesions over anti-VEGF monotherapy [3, 5].”
BackgroundMethodResultInfluentialSelf-citationMatsubara, M., Sakurada, Y., Sugiyama, A., Fukuda, Y., Parikh, R., & Kashiwagi, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237330 · Cited by 10
“[15, 16] Pachydrusen are a new clinical entity characterized by isolated or scattered yellow-whitish drusenoid deposits as seen in the posterior pole of the retina over areas of a thickened choroid.”
BackgroundSahu, Y., Chaudhary, N., Joshi, M., & Gandhi, A. (2020) · International Ophthalmology · doi:10.1007/s10792-020-01620-0 · Cited by 12
Chaikitmongkol, V., Chaovisitsaree, T., Patikulsila, D., Kunavisarut, P., Phasukkijwatana, N., Watanachai, N., Choovuthayakorn, J., Isipradit, S., Boonyot, P., Sangkaew, A., et al. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000551 · Cited by 11
“Feature A — 10 (15) 10 (32) — Feature B — 16 (25) 14 (45) 2 (6) Feature C — 9 (14) 4 (13) 5 (15) Feature D 65 (100) 30 (46) 3 (10) 27 (79) Feature E — — — —”
Lee, J., Kim, K., Kim, E. S., Yu, S., & Kang, M. S. (2023) · BMC Ophthalmology · doi:10.1186/s12886-023-03264-x · Cited by 9
“Koh et al. [10] reported the 6-month clinical outcomes in the EVEREST study, where they observed visual improvement regardless of polyp regression.”
BackgroundInfluentialKimura, M., Sakurada, Y., Fukuda, Y., Matsubara, M., Kotoda, Y., Kasai, Y., Sugiyama, A., Kikushima, W., Tsuru, D. V., & Kashiwagi, K. (2024) · Pharmaceuticals · doi:10.3390/ph17060687 · Cited by 11
“The current first-line treatment for PCV is intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors, and a combination therapy regimen may include photo-dynamic therapy (PDT) [5,6].”
BackgroundOng, J., Selvam, A., Driban, M., Zarnegar, A., Silva, S. I. M. M. A. D., Joy, J. G., Rossi, E. A., Geest, J. P. V., Sahel, J., & Chhablani, J. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101358 · Cited by 10
Metadata
- Authors
- Koh, A., Lee, W. K., Chen, L.-J., Chen, S.-J., Hashad, Y., Kim, H., Lai, T. Y., Pilz, S., Ruamviboonsuk, P., Tokaji, E., Weisberger, A., & Lim, T. H.
- Affiliations
- Eye & Retina Surgeons (SG)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Mackay Memorial Hospital (TW)
- Taipei Veterans General Hospital (TW)
- National Yang Ming University (TW)
- Corresponding author
- Koh, Adrian
- Hashad, Yehia
- Weisberger, Annemarie
- ORCID
- Venue
- Retina
- Published
- 2012-09
- Volume
- 32
- Issue
- 8
- Pages
- 1453-1464
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1976433015
- Cited by
- 587
- References
- 30
- Citations by year
- 2026: 21 · 2025: 39 · 2024: 32 · 2023: 20 · 2022: 31 · 2021: 54 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 63 · 2016: 52 · 2015: 51 · 2014: 39 · 2013: 41 · 2012: 8
- FWCI
- 41.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Retina (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Keywords
- verteporfin photodynamic therapy, ranibizumab, combination therapy, polyp regression, best-corrected visual acuity, anti-VEGF therapy, EVEREST trial
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Choroid, Combined Modality Therapy, Double-Blind Method, Coloring Agents, Female, Fluorescein Angiography, Humans, Indocyanine Green, Male, Middle Aged, Photochemotherapy, Polyps, Porphyrins, Visual Acuity, Choroid Diseases, Treatment Outcome, Photosensitizing Agents, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.